IMMUNITYBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments
IMMUNITYBIO, INC. (IBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments of $500.00 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments · last filed 2021-08-12
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2021-06-30 was $400.00K.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2021-03-31 was $100.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 6 month |
|---|---|---|
| 2021-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $500.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $100.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |